Corcept Therapeutics Incorporated (CORT)
USD 72.77
(1.8%)
USD 72.77
(1.8%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 368.61 Million USD | 29.87% |
| 2022 | 283.83 Million USD | 20.16% |
| 2021 | 236.22 Million USD | 7.33% |
| 2020 | 220.09 Million USD | 16.22% |
| 2019 | 189.37 Million USD | 20.98% |
| 2018 | 156.53 Million USD | 52.28% |
| 2017 | 102.79 Million USD | 48.79% |
| 2016 | 69.08 Million USD | 31.92% |
| 2015 | 52.36 Million USD | -1.73% |
| 2014 | 53.28 Million USD | 3.05% |
| 2013 | 51.71 Million USD | 30.95% |
| 2012 | 39.48 Million USD | 22.13% |
| 2011 | 32.33 Million USD | 17.84% |
| 2010 | 27.43 Million USD | 35.3% |
| 2009 | 20.27 Million USD | 1.91% |
| 2008 | 19.89 Million USD | 56.34% |
| 2007 | 12.72 Million USD | -50.82% |
| 2006 | 25.87 Million USD | 22.3% |
| 2005 | 21.15 Million USD | 31.87% |
| 2004 | 16.04 Million USD | 60.54% |
| 2003 | 9.99 Million USD | -46.82% |
| 2002 | 18.79 Million USD | 134.76% |
| 2001 | 8 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 114.77 Million USD | 12.68% |
| 2024 Q2 | 125.68 Million USD | 9.5% |
| 2024 Q3 | 133.08 Million USD | 5.89% |
| 2023 Q2 | 86.55 Million USD | -3.2% |
| 2023 Q4 | 101.85 Million USD | 12.21% |
| 2023 FY | 368.61 Million USD | 29.87% |
| 2023 Q1 | 89.41 Million USD | 13.07% |
| 2023 Q3 | 90.77 Million USD | 4.88% |
| 2022 Q4 | 79.07 Million USD | 15.52% |
| 2022 Q3 | 68.45 Million USD | -3.09% |
| 2022 Q2 | 70.63 Million USD | 7.57% |
| 2022 FY | 283.83 Million USD | 20.16% |
| 2022 Q1 | 65.66 Million USD | 8.0% |
| 2021 FY | 236.22 Million USD | 7.33% |
| 2021 Q2 | 58.26 Million USD | -0.46% |
| 2021 Q4 | 60.8 Million USD | 3.72% |
| 2021 Q1 | 58.53 Million USD | 8.45% |
| 2021 Q3 | 58.62 Million USD | 0.62% |
| 2020 Q2 | 52.06 Million USD | -2.96% |
| 2020 FY | 220.09 Million USD | 16.22% |
| 2020 Q1 | 53.65 Million USD | 4.31% |
| 2020 Q3 | 60.39 Million USD | 15.98% |
| 2020 Q4 | 53.97 Million USD | -10.63% |
| 2019 Q4 | 51.44 Million USD | 9.34% |
| 2019 Q3 | 47.05 Million USD | 1.74% |
| 2019 FY | 189.37 Million USD | 20.98% |
| 2019 Q2 | 46.24 Million USD | 3.62% |
| 2019 Q1 | 44.63 Million USD | 10.6% |
| 2018 Q3 | 40.16 Million USD | -0.88% |
| 2018 Q4 | 40.35 Million USD | 0.46% |
| 2018 FY | 156.53 Million USD | 52.28% |
| 2018 Q1 | 35.49 Million USD | 16.64% |
| 2018 Q2 | 40.52 Million USD | 14.18% |
| 2017 Q3 | 28.16 Million USD | 28.08% |
| 2017 Q4 | 30.42 Million USD | 8.04% |
| 2017 FY | 102.79 Million USD | 48.79% |
| 2017 Q1 | 22.21 Million USD | 21.76% |
| 2017 Q2 | 21.98 Million USD | -1.01% |
| 2016 Q2 | 17.79 Million USD | 18.08% |
| 2016 Q1 | 15.06 Million USD | 16.32% |
| 2016 FY | 69.08 Million USD | 31.92% |
| 2016 Q4 | 18.24 Million USD | 1.44% |
| 2016 Q3 | 17.98 Million USD | 1.1% |
| 2015 Q3 | 12.9 Million USD | 1.73% |
| 2015 FY | 52.36 Million USD | -1.73% |
| 2015 Q4 | 12.95 Million USD | 0.38% |
| 2015 Q2 | 12.68 Million USD | -8.29% |
| 2015 Q1 | 13.83 Million USD | 16.88% |
| 2014 Q4 | 11.83 Million USD | -2.61% |
| 2014 FY | 53.28 Million USD | 3.05% |
| 2014 Q1 | 17.09 Million USD | 21.34% |
| 2014 Q2 | 12.21 Million USD | -28.51% |
| 2014 Q3 | 12.15 Million USD | -0.55% |
| 2013 Q3 | 12.33 Million USD | -2.51% |
| 2013 Q1 | 12.64 Million USD | 11.48% |
| 2013 FY | 51.71 Million USD | 30.95% |
| 2013 Q4 | 14.08 Million USD | 14.19% |
| 2013 Q2 | 12.65 Million USD | 0.09% |
| 2012 Q1 | 11.02 Million USD | 11.09% |
| 2012 Q4 | 11.33 Million USD | 30.29% |
| 2012 Q3 | 8.7 Million USD | 3.36% |
| 2012 FY | 39.48 Million USD | 22.13% |
| 2012 Q2 | 8.41 Million USD | -23.66% |
| 2011 Q2 | 8.86 Million USD | 24.95% |
| 2011 Q3 | 6.43 Million USD | -27.42% |
| 2011 FY | 32.33 Million USD | 17.84% |
| 2011 Q4 | 9.92 Million USD | 54.23% |
| 2011 Q1 | 7.09 Million USD | -9.28% |
| 2010 Q2 | 6.44 Million USD | 6.28% |
| 2010 Q4 | 7.82 Million USD | 10.12% |
| 2010 FY | 27.43 Million USD | 35.3% |
| 2010 Q3 | 7.1 Million USD | 10.24% |
| 2010 Q1 | 6.06 Million USD | 17.45% |
| 2009 Q3 | 4.67 Million USD | -4.46% |
| 2009 Q1 | 5.55 Million USD | -9.77% |
| 2009 FY | 20.27 Million USD | 1.91% |
| 2009 Q4 | 5.16 Million USD | 10.56% |
| 2009 Q2 | 4.88 Million USD | -12.05% |
| 2008 FY | 19.89 Million USD | 56.34% |
| 2008 Q4 | 6.16 Million USD | 23.99% |
| 2008 Q3 | 4.96 Million USD | 6.0% |
| 2008 Q1 | 4.08 Million USD | -7.6% |
| 2008 Q2 | 4.68 Million USD | 14.79% |
| 2007 Q1 | 2.73 Million USD | -32.68% |
| 2007 Q2 | 1.95 Million USD | -28.62% |
| 2007 Q3 | 3.61 Million USD | 85.25% |
| 2007 FY | 12.72 Million USD | -50.82% |
| 2007 Q4 | 4.41 Million USD | 22.14% |
| 2006 Q1 | 7.1 Million USD | 28.97% |
| 2006 Q4 | 4.06 Million USD | -37.94% |
| 2006 Q3 | 6.54 Million USD | -19.78% |
| 2006 Q2 | 8.16 Million USD | 14.99% |
| 2006 FY | 25.87 Million USD | 22.3% |
| 2005 Q1 | 5.78 Million USD | 4.79% |
| 2005 Q3 | 5.48 Million USD | 24.97% |
| 2005 Q4 | 5.5 Million USD | 0.44% |
| 2005 FY | 21.15 Million USD | 31.87% |
| 2005 Q2 | 4.38 Million USD | -24.21% |
| 2004 Q4 | 5.52 Million USD | 29.7% |
| 2004 Q1 | 2.57 Million USD | 25.76% |
| 2004 Q3 | 4.25 Million USD | 15.25% |
| 2004 FY | 16.04 Million USD | 60.54% |
| 2004 Q2 | 3.69 Million USD | 43.75% |
| 2003 Q3 | 2.16 Million USD | -26.03% |
| 2003 Q2 | 2.92 Million USD | 1.99% |
| 2003 FY | 9.99 Million USD | -46.82% |
| 2003 Q1 | 2.86 Million USD | 0.0% |
| 2003 Q4 | 2.04 Million USD | -5.47% |
| 2002 FY | 18.79 Million USD | 134.76% |
| 2001 FY | 8 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Absci Corporation | 73.66 Million USD | -400.383% |
| Adaptive Biotechnologies Corporation | 321.75 Million USD | -14.562% |
| Alnylam Pharmaceuticals, Inc. | 1.8 Billion USD | 79.522% |
| Alzamend Neuro, Inc. | 9.93 Million USD | -3609.249% |
| Apollomics, Inc. | 54.14 Million USD | -580.85% |
| 180 Life Sciences Corp. | 13.47 Million USD | -2635.018% |
| Atossa Therapeutics, Inc. | 31.37 Million USD | -1074.784% |
| Bicycle Therapeutics plc | 216.92 Million USD | -69.928% |
| Barinthus Biotherapeutics plc | 84.71 Million USD | -335.115% |
| BioXcel Therapeutics, Inc. | 171.9 Million USD | -114.431% |
| CASI Pharmaceuticals, Inc. | 47 Million USD | -684.181% |
| Chimerix, Inc. | 93.38 Million USD | -294.706% |
| CRISPR Therapeutics AG | 463.49 Million USD | 20.471% |
| Contineum Therapeutics, Inc. Class A Common Stock | 33.72 Million USD | -992.896% |
| EyePoint Pharmaceuticals, Inc. | 116.45 Million USD | -216.533% |
| Fortress Biotech, Inc. | 200.19 Million USD | -84.126% |
| Fortress Biotech, Inc. | 200.19 Million USD | -84.126% |
| Gritstone bio, Inc. | 148.37 Million USD | -148.434% |
| Allakos Inc. | 196.05 Million USD | -88.014% |
| Boundless Bio, Inc. Common Stock | 54.79 Million USD | -572.699% |
| Cara Therapeutics, Inc. | 142.46 Million USD | -158.742% |
| Cytokinetics, Incorporated | 173.61 Million USD | -112.319% |
| enGene Holdings Inc. Common Stock | 25.88 Million USD | -1324.037% |
| Innoviva, Inc. | 132.15 Million USD | -178.926% |
| Hoth Therapeutics, Inc. | 7.69 Million USD | -4691.997% |
| NLS Pharmaceutics AG | 11.8 Million USD | -3021.962% |
| RAPT Therapeutics, Inc. | 127.06 Million USD | -190.104% |
| Salarius Pharmaceuticals, Inc. | 12.89 Thousand USD | -2858687.033% |
| Terns Pharmaceuticals, Inc. | 102.55 Million USD | -259.418% |
| Vigil Neuroscience, Inc. | 88.86 Million USD | -314.795% |
| ImmuCell Corporation | 9.61 Million USD | -3732.777% |
| IDEAYA Biosciences, Inc. | 157.81 Million USD | -133.574% |
| Incyte Corporation | 1.19 Billion USD | 69.037% |
| Inovio Pharmaceuticals, Inc. | 132.55 Million USD | -178.082% |
| Lexaria Bioscience Corp. | 6.72 Million USD | -5378.181% |
| Mustang Bio, Inc. | 48.5 Million USD | -660.009% |
| MiMedx Group, Inc. | 229.72 Million USD | -60.457% |
| MEI Pharma, Inc. | 34.78 Million USD | -959.687% |
| MacroGenics, Inc. | 217.21 Million USD | -69.699% |
| Monopar Therapeutics Inc. | 8.83 Million USD | -4073.958% |
| Mereo BioPharma Group plc | 35.84 Million USD | -928.436% |
| Marker Therapeutics, Inc. | 17.89 Million USD | -1960.147% |
| Marinus Pharmaceuticals, Inc. | 160.54 Million USD | -129.608% |
| Maravai LifeSciences Holdings, Inc. | 171.85 Million USD | -114.496% |
| Minerva Neurosciences, Inc. | 23.08 Million USD | -1496.511% |
| NeuroBo Pharmaceuticals, Inc. | 15.88 Million USD | -2220.358% |
| NeuroSense Therapeutics Ltd. | 10.28 Million USD | -3483.977% |
| NextCure, Inc. | 67.63 Million USD | -444.986% |
| Orchestra BioMed Holdings, Inc. | 54.08 Million USD | -581.605% |
| Ocuphire Pharma, Inc. | 29.6 Million USD | -1145.058% |
| Onconetix, Inc. | 34.9 Million USD | -955.97% |
| Oncternal Therapeutics, Inc. | 12.74 Million USD | -2791.982% |
| Opthea Limited | 191.96 Million USD | -92.018% |
| Ovid Therapeutics Inc. | 59.67 Million USD | -517.718% |
| Psyence Biomedical Ltd. | 2.75 Million USD | -13296.352% |
| PDS Biotechnology Corporation | 43.04 Million USD | -756.336% |
| Precigen, Inc. | 84.18 Million USD | -337.88% |
| Pieris Pharmaceuticals, Inc. | 72.56 Million USD | -407.968% |
| Prime Medicine, Inc. | 186.63 Million USD | -97.5% |
| PureTech Health plc | 144.59 Million USD | -154.924% |
| Rocket Pharmaceuticals, Inc. | 259.65 Million USD | -41.96% |
| Regeneron Pharmaceuticals, Inc. | 2.81 Billion USD | 86.907% |
| Replimune Group, Inc. | 234.77 Million USD | -57.008% |
| Revelation Biosciences, Inc. | 8.65 Million USD | -4158.13% |
| Rigel Pharmaceuticals, Inc. | 130.26 Million USD | -182.975% |
| TransCode Therapeutics, Inc. | 19.41 Million USD | -1798.25% |
| Revolution Medicines, Inc. Warrant | 498.76 Million USD | 26.095% |
| Reviva Pharmaceuticals Holdings, Inc. | 24.3 Million USD | -1416.509% |
| Sesen Bio, Inc. | 78.38 Million USD | -370.282% |
| Sangamo Therapeutics, Inc. | 228.68 Million USD | -61.191% |
| Solid Biosciences Inc. | 104.31 Million USD | -253.364% |
| Syndax Pharmaceuticals, Inc. | 229.95 Million USD | -60.298% |
| SciSparc Ltd. | 9.01 Million USD | -3990.689% |
| Sutro Biopharma, Inc. | 243 Million USD | -51.687% |
| TG Therapeutics, Inc. | 198.47 Million USD | -85.722% |
| Tonix Pharmaceuticals Holding Corp. | 121.4 Million USD | -203.617% |
| Titan Pharmaceuticals, Inc. | 7.46 Million USD | -4840.517% |
| Travere Therapeutics, Inc. | 472 Million USD | 21.905% |
| UroGen Pharma Ltd. | 138.88 Million USD | -165.402% |
| Verrica Pharmaceuticals Inc. | 70.59 Million USD | -422.158% |
| XOMA Corporation | 46.46 Million USD | -693.345% |
| Zentalis Pharmaceuticals, Inc. | 252.55 Million USD | -45.955% |
| AbCellera Biologics Inc. | 275.23 Million USD | -33.928% |
| Longboard Pharmaceuticals, Inc. | 56.75 Million USD | -549.434% |
| Cassava Sciences, Inc. | 105.95 Million USD | -247.888% |
| Corbus Pharmaceuticals Holdings, Inc. | 13.9 Million USD | -2550.047% |
| Precision BioSciences, Inc. | 92.46 Million USD | -298.659% |
| Dyadic International, Inc. | 9.15 Million USD | -3927.36% |
| Intensity Therapeutics, Inc. | 8.31 Million USD | -4330.965% |
| Eton Pharmaceuticals, Inc. | 22.25 Million USD | -1556.46% |
| VYNE Therapeutics Inc. | 29.68 Million USD | -1141.87% |
| Tenaya Therapeutics, Inc. | 131.19 Million USD | -180.969% |
| IGM Biosciences, Inc. | 265.59 Million USD | -38.789% |
| X4 Pharmaceuticals, Inc. | 107.52 Million USD | -242.825% |
| Acelyrin, Inc. | 422.06 Million USD | 12.664% |
| Abeona Therapeutics Inc. | 17.93 Million USD | -1954.808% |
| Ligand Pharmaceuticals Incorporated | 84.32 Million USD | -337.143% |
| Inhibikase Therapeutics, Inc. | 6.73 Million USD | -5375.565% |
| Arcturus Therapeutics Holdings Inc. | 245 Million USD | -50.451% |
| Syros Pharmaceuticals, Inc. | 30.77 Million USD | -1097.92% |
| Senti Biosciences, Inc. | 94.7 Million USD | -289.221% |
| Mesoblast Limited | 5.9 Million USD | -6145.544% |
| Kymera Therapeutics, Inc. | 244.12 Million USD | -50.995% |
| ChromaDex Corporation | 56.37 Million USD | -553.811% |
| BriaCell Therapeutics Corp. | 33.33 Million USD | -1005.944% |
| Akebia Therapeutics, Inc. | 201.11 Million USD | -83.284% |
| Dermata Therapeutics, Inc. | 8.04 Million USD | -4483.64% |
| Seer, Inc. | 110.49 Million USD | -233.616% |
| Xeris Biopharma Holdings, Inc. | 168.43 Million USD | -118.844% |
| Novavax, Inc. | 779.12 Million USD | 52.689% |
| Virpax Pharmaceuticals, Inc. | 15.68 Million USD | -2249.375% |
| Fate Therapeutics, Inc. | 254.04 Million USD | -45.098% |
| Checkpoint Therapeutics, Inc. | 52.25 Million USD | -605.464% |
| Lyell Immunopharma, Inc. | 247.13 Million USD | -49.152% |
| Celcuity Inc. | 66.23 Million USD | -456.561% |
| ContextLogic Inc. | 387 Million USD | 4.751% |
| Phathom Pharmaceuticals, Inc. | 167.82 Million USD | -119.638% |
| HOOKIPA Pharma Inc. | 32.74 Million USD | -1025.67% |
| Jazz Pharmaceuticals plc | 3.25 Billion USD | 88.678% |
| Amarin Corporation plc | 272.35 Million USD | -35.341% |
| AnaptysBio, Inc. | 181.56 Million USD | -103.016% |
| Aptevo Therapeutics Inc. | 28.87 Million USD | -1176.446% |
| Aptorum Group Limited | 10.56 Thousand USD | -3488561.745% |
| Cartesian Therapeutics, Inc. | 110.86 Million USD | -232.481% |
| Arrowhead Pharmaceuticals, Inc. | 445.73 Million USD | 17.303% |
| Ardelyx, Inc. | 169.93 Million USD | -116.911% |
| Celularity Inc. | 215.05 Million USD | -71.401% |
| Omeros Corporation | 94.75 Million USD | -289.032% |
| Humacyte, Inc. | 23.49 Million USD | -1468.762% |
| Immunocore Holdings plc | 308.04 Million USD | -19.664% |
| IO Biotech, Inc. | 91.44 Million USD | -303.106% |
| GT Biopharma, Inc. | 13.57 Million USD | -2615.174% |
| Cabaletta Bio, Inc. | 74.66 Million USD | -393.721% |
| Summit Therapeutics Inc. | 87.68 Million USD | -320.377% |
| Alaunos Therapeutics, Inc. | 29.46 Million USD | -1150.847% |
| Pulmatrix, Inc. | 22.03 Million USD | -1572.62% |
| Intellia Therapeutics, Inc. | 551.56 Million USD | 33.17% |
| Evogene Ltd. | 27.79 Million USD | -1226.42% |
| CorMedix Inc. | 48.95 Million USD | -652.918% |
| BioLineRx Ltd. | 50.8 Million USD | -625.586% |
| VistaGen Therapeutics, Inc. | 34.08 Million USD | -981.449% |
| Sagimet Biosciences Inc. | 32.74 Million USD | -1025.877% |
| PTC Therapeutics, Inc. | 1.31 Billion USD | 71.901% |
| scPharmaceuticals Inc. | 65.17 Million USD | -465.547% |
| Fulcrum Therapeutics, Inc. | 113.46 Million USD | -224.857% |
| NLS Pharmaceutics AG | 11.8 Million USD | -3021.962% |
| Reviva Pharmaceuticals Holdings, Inc. | 24.3 Million USD | -1416.509% |
| Akero Therapeutics, Inc. | 172.87 Million USD | -113.231% |
| Eliem Therapeutics, Inc. | 37.4 Million USD | -885.383% |
| Lisata Therapeutics, Inc. | 25.7 Million USD | -1333.842% |
| Stoke Therapeutics, Inc. | 123.55 Million USD | -198.343% |
| Reneo Pharmaceuticals, Inc. | 83.05 Million USD | -343.827% |
| Outlook Therapeutics, Inc. | 53.12 Million USD | -593.84% |
| ProMIS Neurosciences, Inc. | 8.45 Million USD | -4260.86% |
| Daré Bioscience, Inc. | 33.6 Million USD | -996.753% |
| bluebird bio, Inc. | 240.23 Million USD | -53.44% |
| BioMarin Pharmaceutical Inc. | 1.74 Billion USD | 78.892% |
| DBV Technologies S.A. | 92.16 Million USD | -299.97% |
| Avidity Biosciences, Inc. | 245.15 Million USD | -50.357% |
| Galecto, Inc. | 35.62 Million USD | -934.642% |
| Sensei Biotherapeutics, Inc. | 37.06 Million USD | -894.528% |
| Spruce Biosciences, Inc. | 62.08 Million USD | -493.75% |
| Inhibrx Biosciences, Inc. | 219.83 Million USD | -67.68% |
| GlycoMimetics, Inc. | 39.28 Million USD | -838.295% |
| Arcutis Biotherapeutics, Inc. | 295.72 Million USD | -24.649% |
| ADMA Biologics, Inc. | 66.58 Million USD | -453.588% |
| Clene Inc. | 41.07 Million USD | -797.456% |
| Recursion Pharmaceuticals, Inc. | 352.04 Million USD | -4.705% |
| Aptose Biosciences Inc. | 52.35 Million USD | -604.049% |
| ZyVersa Therapeutics, Inc. | 14.41 Million USD | -2457.963% |
| Soligenix, Inc. | 7.79 Million USD | -4628.674% |
| Century Therapeutics, Inc. | 56.07 Million USD | -557.402% |
| Kura Oncology, Inc. | 165.8 Million USD | -122.318% |
| Surrozen, Inc. | 18.55 Million USD | -1887.127% |
| TScan Therapeutics, Inc. | 114.5 Million USD | -221.912% |
| Ocean Biomedical, Inc. | 2.48 Million USD | -14753.571% |
| CytomX Therapeutics, Inc. | 107.69 Million USD | -242.264% |
| Autolus Therapeutics plc | 196.72 Million USD | -87.373% |
| Mineralys Therapeutics, Inc. | 84.65 Million USD | -335.418% |
| Eterna Therapeutics Inc. | 19.38 Million USD | -1801.728% |
| Caribou Biosciences, Inc. | 150.53 Million USD | -144.866% |
| GRI Bio, Inc. | 11.33 Million USD | -3153.416% |
| Xenetic Biosciences, Inc. | 7.05 Million USD | -5124.314% |
| Janux Therapeutics, Inc. | 81.06 Million USD | -354.728% |
| INmune Bio, Inc. | 29.89 Million USD | -1132.981% |
| Heron Therapeutics, Inc. | 172.55 Million USD | -113.621% |
| SAB Biotherapeutics, Inc. | 40.31 Million USD | -814.345% |
| Pasithea Therapeutics Corp. | 15.97 Million USD | -2206.801% |
| Tenax Therapeutics, Inc. | 8.23 Million USD | -4376.738% |
| Jaguar Health, Inc. | 42.01 Million USD | -777.334% |
| Entero Therapeutics, Inc. | 15.74 Million USD | -2241.65% |
| Milestone Pharmaceuticals Inc. | 62.09 Million USD | -493.597% |
| Clearside Biomedical, Inc. | 32.71 Million USD | -1026.737% |
| Atara Biotherapeutics, Inc. | 275.69 Million USD | -33.704% |
| Coherus BioSciences, Inc. | 301.45 Million USD | -22.279% |
| Verastem, Inc. | 92.08 Million USD | -300.3% |
| Pliant Therapeutics, Inc. | 185.72 Million USD | -98.472% |
| Histogen Inc. | 14.27 Million USD | -2482.763% |
| Aprea Therapeutics, Inc. | 16.04 Million USD | -2196.914% |
| ACADIA Pharmaceuticals Inc. | 754.08 Million USD | 51.118% |
| Surrozen, Inc. | 18.55 Million USD | -1887.127% |
| Organovo Holdings, Inc. | 14.91 Million USD | -2371.418% |
| Lixte Biotechnology Holdings, Inc. | 5.09 Million USD | -7141.55% |
| Cadrenal Therapeutics, Inc. Common Stock | 7.63 Million USD | -4729.288% |
| Centessa Pharmaceuticals plc | 178.13 Million USD | -106.927% |
| Hepion Pharmaceuticals, Inc. | 48.44 Million USD | -660.841% |
| BioRestorative Therapies, Inc. | 15.36 Million USD | -2298.791% |
| Kronos Bio, Inc. | 128.11 Million USD | -187.713% |
| Turnstone Biologics Corp. | 78.33 Million USD | -370.54% |
| Synaptogenix, Inc. | 8.31 Million USD | -4333.708% |
| Tiziana Life Sciences Ltd | 14.58 Million USD | -2427.163% |
| Entrada Therapeutics, Inc. | 132.17 Million USD | -178.882% |
| Aurinia Pharmaceuticals Inc. | 253.05 Million USD | -45.664% |
| Exelixis, Inc. | 1.58 Billion USD | 76.77% |
| Nurix Therapeutics, Inc. | 232.05 Million USD | -58.85% |
| Apellis Pharmaceuticals, Inc. | 855.2 Million USD | 56.898% |
| Jasper Therapeutics, Inc. | 68.86 Million USD | -435.299% |
| ESSA Pharma Inc. | 32.13 Million USD | -1047.105% |
| TNF Pharmaceuticals, Inc. | 16.36 Million USD | -2153.1% |
| Avid Bioservices, Inc. | 25.99 Million USD | -1317.957% |
| Insmed Incorporated | 949.26 Million USD | 61.169% |
| MediWound Ltd. | 18.86 Million USD | -1853.636% |
| OmniAb, Inc. | 83.89 Million USD | -339.373% |
| Alector, Inc. | 248.8 Million USD | -48.155% |
| Seres Therapeutics, Inc. | 234.3 Million USD | -57.319% |
| Zai Lab Limited | 547.47 Million USD | 32.671% |
| AlloVir, Inc. | 180.93 Million USD | -103.728% |
| Revance Therapeutics, Inc. | 398.65 Million USD | 7.536% |
| ORIC Pharmaceuticals, Inc. | 110.78 Million USD | -232.742% |
| Aura Biosciences, Inc. | 84.99 Million USD | -333.707% |
| Immunic, Inc. | 99.22 Million USD | -271.499% |
| Tarsus Pharmaceuticals, Inc. | 159.01 Million USD | -131.814% |
| Veracyte, Inc. | 357.93 Million USD | -2.984% |
| InMed Pharmaceuticals Inc. | 9.01 Billion USD | 95.911% |
| FibroGen, Inc. | 398.11 Million USD | 7.41% |
| SeaStar Medical Holding Corporation | 14.21 Million USD | -2494.032% |
| Catalyst Pharmaceuticals, Inc. | 259.42 Million USD | -42.088% |
| Adial Pharmaceuticals, Inc. | 6.88 Million USD | -5251.551% |
| Sonnet BioTherapeutics Holdings, Inc. | 7.12 Million USD | -5072.97% |
| Cyclacel Pharmaceuticals, Inc. | 25.87 Million USD | -1324.698% |
| Amylyx Pharmaceuticals, Inc. | 316.54 Million USD | -16.449% |
| Fortrea Holdings Inc. | 457.3 Million USD | 19.394% |
| KalVista Pharmaceuticals, Inc. | 54.27 Million USD | -579.119% |
| XBiotech Inc. | 37.51 Million USD | -882.703% |
| Jasper Therapeutics, Inc. | 68.86 Million USD | -435.299% |
| Keros Therapeutics, Inc. | 169.27 Million USD | -117.757% |
| SELLAS Life Sciences Group, Inc. | 37.86 Million USD | -873.387% |
| Lyra Therapeutics, Inc. | 20.64 Million USD | -1685.132% |
| Foghorn Therapeutics Inc. | 142.06 Million USD | -159.474% |
| Agenus Inc. | 78.18 Million USD | -371.473% |
| Y-mAbs Therapeutics, Inc. | 99.07 Million USD | -272.053% |
| Theravance Biopharma, Inc. | 110.71 Million USD | -232.935% |
| Ultragenyx Pharmaceutical Inc. | 958.24 Million USD | 61.533% |
| Metagenomi, Inc. Common Stock | 28.84 Million USD | -1177.906% |
| BioCryst Pharmaceuticals, Inc. | 430.64 Million USD | 14.404% |
| Gain Therapeutics, Inc. | 22.3 Million USD | -1552.353% |
| C4 Therapeutics, Inc. | 159.78 Million USD | -130.69% |
| Creative Medical Technology Holdings, Inc. | 5.53 Million USD | -6564.536% |
| Chemomab Therapeutics Ltd. | 25.45 Million USD | -1347.865% |
| Lantern Pharma Inc. | 17.87 Million USD | -1961.869% |
| Eledon Pharmaceuticals, Inc. | 43 Million USD | -757.237% |
| Ainos, Inc. | 12.95 Million USD | -2745.84% |
| Pluri Inc. | 22.48 Million USD | -1539.733% |
| Prothena Corporation plc | 282.4 Million USD | -30.526% |
| Adaptimmune Therapeutics plc | 200.02 Million USD | -84.286% |
| Rallybio Corporation | 78.93 Million USD | -366.999% |
| Kodiak Sciences Inc. | 277.32 Million USD | -32.919% |
| Cue Biopharma, Inc. | 19.54 Million USD | -1786.255% |
| MeiraGTx Holdings plc | 151.07 Million USD | -143.988% |
| Annexon, Inc. | 143.72 Million USD | -156.474% |
| Assembly Biosciences, Inc. | 22.9 Million USD | -1509.027% |
| Moderna, Inc. | 6.39 Billion USD | 94.235% |
| Cocrystal Pharma, Inc. | 3.39 Million USD | -10773.51% |
| Cidara Therapeutics, Inc. | 86.86 Million USD | -324.35% |
| Blueprint Medicines Corporation | 722.86 Million USD | 49.007% |
| Immix Biopharma, Inc. | 16.14 Million USD | -2183.684% |
| CalciMedica, Inc. | 21.81 Million USD | -1589.563% |
| Monte Rosa Therapeutics, Inc. | 143.31 Million USD | -157.211% |
| Scholar Rock Holding Corporation | 171.29 Million USD | -115.191% |
| Wave Life Sciences Ltd. | 181.3 Million USD | -103.315% |
| Sana Biotechnology, Inc. | 294.94 Million USD | -24.979% |
| Elicio Therapeutics, Inc. | 34.57 Million USD | -966.123% |
| Adlai Nortye Ltd. American Depositary Shares | 72.55 Million USD | -408.073% |
| Nutriband Inc. | 5.73 Million USD | -6328.497% |
| Protara Therapeutics, Inc. | 43.61 Million USD | -745.188% |
| Vor Biopharma Inc. | 126.03 Million USD | -192.466% |
| Roivant Sciences Ltd. | 1.18 Billion USD | 69.003% |
| Alkermes plc | 996.24 Million USD | 63.0% |
| ProKidney Corp. | 151.52 Million USD | -143.273% |
| Applied Therapeutics, Inc. | 74.17 Million USD | -396.949% |
| Arcellx, Inc. | 200.19 Million USD | -84.123% |
| BridgeBio Pharma, Inc. | 614.22 Million USD | 39.988% |
| Tango Therapeutics, Inc. | 150.7 Million USD | -144.6% |
| Galectin Therapeutics Inc. | 38.07 Million USD | -868.197% |
| Atai Life Sciences N.V. | 125.78 Million USD | -193.049% |
| Renovaro Biosciences Inc. | 81.63 Million USD | -351.513% |
| Aerovate Therapeutics, Inc. | 81.4 Million USD | -352.79% |
| MediciNova, Inc. | 10.9 Million USD | -3281.679% |
| Praxis Precision Medicines, Inc. | 128.82 Million USD | -186.145% |
| Cardio Diagnostics Holdings, Inc. | 7.25 Million USD | -4977.633% |
| GeoVax Labs, Inc. | 6.02 Million USD | -6020.913% |
| Axsome Therapeutics, Inc. | 476.36 Million USD | 22.619% |
| Biomea Fusion, Inc. | 126.13 Million USD | -192.236% |
| RenovoRx, Inc. | 11.39 Million USD | -3134.574% |
| Cullinan Oncology, Inc. | 191.08 Million USD | -92.901% |
| Geron Corporation | 70.44 Million USD | -423.292% |
| NRx Pharmaceuticals, Inc. | 27.58 Million USD | -1236.422% |
| 4D Molecular Therapeutics, Inc. | 133.59 Million USD | -175.928% |
| Dyne Therapeutics, Inc. | 242.16 Million USD | -52.217% |
| Kiniksa Pharmaceuticals, Ltd. | 262.04 Million USD | -40.666% |
| Royalty Pharma plc | 862.4 Million USD | 57.258% |
| Ventyx Biosciences, Inc. | 207.99 Million USD | -77.222% |
| Imunon, Inc. | 20.31 Million USD | -1714.891% |
| BioAtla, Inc. | 129.68 Million USD | -184.232% |
| Allogene Therapeutics, Inc. | 84.91 Million USD | -334.08% |
| Larimar Therapeutics, Inc. | 41.75 Million USD | -782.734% |
| Mersana Therapeutics, Inc. | 207.81 Million USD | -77.378% |
| Structure Therapeutics Inc. | 102.77 Million USD | -258.659% |
| 89bio, Inc. | 151.2 Million USD | -143.785% |
| Kezar Life Sciences, Inc. | 111.17 Million USD | -231.572% |
| aTyr Pharma, Inc. | 12.97 Million USD | -2740.065% |
| Aligos Therapeutics, Inc. | 103.65 Million USD | -255.611% |
| Viridian Therapeutics, Inc. | 254.76 Million USD | -44.688% |
| EyeGate Pharmaceuticals, Inc. | 8.22 Million USD | -4381.706% |
| Akari Therapeutics, Plc | 16.8 Million USD | -2093.336% |
| Tevogen Bio Holdings Inc. | 2.27 Million USD | -16110.064% |
| Halozyme Therapeutics, Inc. | 299.31 Million USD | -23.151% |
| Lexicon Pharmaceuticals, Inc. | 172.86 Million USD | -113.232% |
| Liquidia Corporation | 87.98 Million USD | -318.953% |
| Entera Bio Ltd. | 8.86 Million USD | -4060.406% |
| GH Research PLC | 41.22 Million USD | -794.212% |
| Vericel Corporation | 142.04 Million USD | -159.513% |
| Arbutus Biopharma Corporation | 22.54 Million USD | -1535.078% |
| Xencor, Inc. | 306.97 Million USD | -20.078% |
| 60 Degrees Pharmaceuticals, Inc. | 4.93 Million USD | -7371.452% |
| Pasithea Therapeutics Corp. | 15.97 Million USD | -2206.801% |
| Coeptis Therapeutics Holdings, Inc. | 20.48 Million USD | -1698.995% |
| Vaxcyte, Inc. | 468.04 Million USD | 21.244% |
| Xenon Pharmaceuticals Inc. | 46.54 Million USD | -691.999% |
| Vanda Pharmaceuticals Inc. | 191.79 Million USD | -92.19% |
| Lexaria Bioscience Corp. | 6.72 Million USD | -5378.181% |
| Portage Biotech Inc. | 18.19 Million USD | -1925.452% |
| Cardio Diagnostics Holdings, Inc. | 7.25 Million USD | -4977.633% |
| Olema Pharmaceuticals, Inc. | 104.96 Million USD | -251.189% |
| OncoCyte Corporation | 25.63 Million USD | -1337.813% |
| Qualigen Therapeutics, Inc. | 6.09 Million USD | -5947.175% |
| Processa Pharmaceuticals, Inc. | 11.45 Million USD | -3117.335% |
| Purple Biotech Ltd. | -22.46 Million USD | 1740.682% |
| Tempest Therapeutics, Inc. | 29.15 Million USD | -1164.232% |
| Sol-Gel Technologies Ltd. | 30.85 Million USD | -1094.504% |
| Rhythm Pharmaceuticals, Inc. | 252.48 Million USD | -45.995% |
| CollPlant Biotechnologies Ltd. | 16.48 Million USD | -2136.723% |
| Moleculin Biotech, Inc. | 29.63 Million USD | -1144.008% |
| United Therapeutics Corporation | 885.1 Million USD | 58.354% |
| HilleVax, Inc. | 133.34 Million USD | -176.435% |
| Silo Pharma, Inc. | 3.92 Million USD | -9298.917% |
| Telomir Pharmaceuticals, Inc. Common Stock | 3.94 Million USD | -9250.774% |
| Pharming Group N.V. | 225.49 Million USD | -63.471% |
| Tharimmune, Inc. | 9.45 Million USD | -3798.503% |
| Genprex, Inc. | 31.06 Million USD | -1086.752% |
| Apogee Therapeutics, Inc. | 93 Million USD | -296.344% |
| Neumora Therapeutics, Inc. Common Stock | 187.52 Million USD | -96.566% |
| Pyxis Oncology, Inc. | 82.19 Million USD | -348.455% |
| XTL Biopharmaceuticals Ltd. | 765 Thousand USD | -48084.575% |
| Virios Therapeutics, Inc. | 5.44 Million USD | -6667.349% |
| OKYO Pharma Limited | 8243.57 USD | -4471409.31% |
| Savara Inc. | 15.74 Million USD | -2241.137% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | -2011.543% |
| Curis, Inc. | 58.35 Million USD | -531.672% |
| Carmell Therapeutics Corporation | 5.09 Million USD | -7138.348% |
| Achieve Life Sciences, Inc. | 27.02 Million USD | -1264.118% |
| BeiGene, Ltd. | 3.28 Billion USD | 88.784% |
| Protagonist Therapeutics, Inc. | 153.65 Million USD | -139.901% |
| Erasca, Inc. | 141.52 Million USD | -160.457% |
| Protagenic Therapeutics, Inc. | 4.52 Million USD | -8042.569% |
| Protagenic Therapeutics, Inc. | 4.52 Million USD | -8042.569% |
| Vincerx Pharma, Inc. | 42.6 Million USD | -765.104% |
| Fresh Tracks Therapeutics, Inc. | 14.36 Million USD | -2465.864% |
| Acrivon Therapeutics, Inc. Common Stock | 66.7 Million USD | -452.633% |
| Celldex Therapeutics, Inc. | 43.41 Million USD | -749.063% |
| Cogent Biosciences, Inc. | 208.13 Million USD | -77.107% |
| Adicet Bio, Inc. | 152.03 Million USD | -142.447% |
| Amicus Therapeutics, Inc. | 427.65 Million USD | 13.805% |
| Aditxt, Inc. | 25.95 Million USD | -1320.428% |
| Adagene Inc. | 41.83 Million USD | -781.186% |
| Estrella Immunopharma, Inc. | 7.31 Million USD | -4942.504% |
| Quantum-Si incorporated | 111.65 Million USD | -230.123% |
| Acurx Pharmaceuticals, Inc. | 14.57 Million USD | -2428.59% |
| Voyager Therapeutics, Inc. | 35.82 Million USD | -929.01% |
| Compugen Ltd. | 43.97 Million USD | -738.307% |
| Generation Bio Co. | 144.46 Million USD | -155.153% |
| Astria Therapeutics, Inc. | 83.03 Million USD | -343.95% |
| Black Diamond Therapeutics, Inc. | 86.46 Million USD | -326.338% |
| Invivyd, Inc. | 205.75 Million USD | -79.151% |
| Relay Therapeutics, Inc. | 72.15 Million USD | -410.833% |
| Quoin Pharmaceuticals, Ltd. | 9.37 Million USD | -3830.392% |
| Spero Therapeutics, Inc. | 75.25 Million USD | -389.824% |
| Artelo Biosciences, Inc. | 10.28 Million USD | -3483.28% |
| 2seventy bio, Inc. | 289.88 Million USD | -27.157% |
| Instil Bio, Inc. | 85.78 Million USD | -329.693% |
| Capricor Therapeutics, Inc. | 12.8 Million USD | -2778.008% |
| Elevai Labs, Inc. Common Stock | 1.13 Million USD | -32388.85% |
| GeoVax Labs, Inc. | 6.02 Million USD | -6020.913% |
| Citius Pharmaceuticals, Inc. | 36.73 Million USD | -903.517% |
| Relmada Therapeutics, Inc. | 103.7 Million USD | -255.453% |
| ALX Oncology Holdings Inc. | 170.27 Million USD | -116.477% |
| Vir Biotechnology, Inc. | 767.72 Million USD | 51.986% |
| Evaxion Biotech A/S | 22.27 Million USD | -1555.195% |
| Ocular Therapeutix, Inc. | 135.54 Million USD | -171.95% |
| Verve Therapeutics, Inc. | 234.88 Million USD | -56.935% |
| Tyra Biosciences, Inc. | 79.94 Million USD | -361.082% |
| Cingulate Inc. | 22.75 Million USD | -1519.618% |
| Galmed Pharmaceuticals Ltd. | -7.49 Million USD | 5020.075% |
| Unity Biotechnology, Inc. | 44.66 Million USD | -725.245% |
| Connect Biopharma Holdings Limited | 62.07 Million USD | -493.827% |
| Clearmind Medicine Inc. | 8.74 Million USD | -4116.877% |
| Bolt Biotherapeutics, Inc. | 84.07 Million USD | -338.448% |
| CERo Therapeutics Holdings, Inc. | 2.93 Million USD | -12467.811% |
| Viking Therapeutics, Inc. | 100.82 Million USD | -265.589% |
| Madrigal Pharmaceuticals, Inc. | 380.49 Million USD | 3.123% |
| ImmunityBio, Inc. | 362.87 Million USD | -1.582% |
| Korro Bio, Inc. | 84.53 Million USD | -336.052% |
| Kineta, Inc. | 21.15 Million USD | -1642.352% |
| BioVie Inc. | 31.95 Million USD | -1053.708% |
| Codexis, Inc. | 66.51 Million USD | -454.154% |
| Celularity Inc. | 215.05 Million USD | -71.401% |
| Aileron Therapeutics, Inc. | 16.27 Million USD | -2164.758% |
| Crinetics Pharmaceuticals, Inc. | 226.62 Million USD | -62.656% |
| Virax Biolabs Group Limited | 6.54 Million USD | -5530.189% |
| Cibus, Inc. | 320.3 Million USD | -15.082% |
| IN8bio, Inc. | 30.33 Million USD | -1115.058% |
| Adverum Biotechnologies, Inc. | 127.59 Million USD | -188.901% |
| Avalo Therapeutics, Inc. | 640 Thousand USD | -57495.625% |
| Ionis Pharmaceuticals, Inc. | 779.58 Million USD | 52.717% |
| Eyenovia, Inc. | 25.4 Million USD | -1350.86% |
| Puma Biotechnology, Inc. | 140.31 Million USD | -162.703% |
| Conduit Pharmaceuticals Inc. | 5.56 Million USD | -6527.328% |
| Elevation Oncology, Inc. | 45.44 Million USD | -711.117% |
| Xilio Therapeutics, Inc. | 79.13 Million USD | -365.813% |
| Cardiff Oncology, Inc. | 45.9 Million USD | -703.076% |
| Enanta Pharmaceuticals, Inc. | 216.41 Million USD | -70.33% |
| Regulus Therapeutics Inc. | 9.95 Million USD | -3602.039% |
| Moolec Science SA | 52.75 Million USD | -598.782% |
| Acumen Pharmaceuticals, Inc. | 61.13 Million USD | -502.918% |
| LAVA Therapeutics N.V. | 46.54 Million USD | -692.033% |
| Atea Pharmaceuticals, Inc. | 94.07 Million USD | -291.84% |
| Compass Therapeutics, Inc. | 48.47 Million USD | -660.448% |
| Greenwich LifeSciences, Inc. | 9.32 Million USD | -3851.729% |
| TFF Pharmaceuticals, Inc. | 22.62 Million USD | -1528.97% |
| Humacyte, Inc. | 23.49 Million USD | -1468.762% |
| PMV Pharmaceuticals, Inc. | 80.13 Million USD | -360.006% |
| Avenue Therapeutics, Inc. | 14.54 Million USD | -2435.158% |
| Genelux Corporation | 24.33 Million USD | -1414.74% |
| Trevi Therapeutics, Inc. | 33.92 Million USD | -986.614% |
| Notable Labs, Ltd. | 14.77 Million USD | -2395.68% |
| Immunovant, Inc. | 282.7 Million USD | -30.386% |
| Quantum-Si incorporated | 111.65 Million USD | -230.123% |
| DiaMedica Therapeutics Inc. | 21.26 Million USD | -1633.258% |
| Vera Therapeutics, Inc. | 102.01 Million USD | -261.342% |
| Acasti Pharma Inc. | 11.3 Million USD | -3161.764% |
| MiNK Therapeutics, Inc. | 22.92 Million USD | -1508.177% |
| Soleno Therapeutics, Inc. | 41.38 Million USD | -790.711% |
| PepGen Inc. | 84.76 Million USD | -334.858% |
| Nuvectis Pharma, Inc. | 22.89 Million USD | -1509.87% |
| BriaCell Therapeutics Corp. | 32.72 Million USD | -1026.374% |
| Immuneering Corporation | 58.41 Million USD | -531.046% |
| Lixte Biotechnology Holdings, Inc. | 5.09 Million USD | -7141.55% |
| Belite Bio, Inc | 31.66 Million USD | -1063.989% |
| XOMA Corporation | 46.46 Million USD | -693.345% |
| ARS Pharmaceuticals, Inc. | 67.55 Million USD | -445.688% |
| Bionomics Limited | 17.89 Billion USD | 97.94% |
| Alpha Tau Medical Ltd. | -35.68 Million USD | 1133.105% |
| uniQure N.V. | 285.08 Million USD | -29.299% |
| Estrella Immunopharma, Inc. | 7.31 Million USD | -4942.504% |
| Poseida Therapeutics, Inc. | 194.2 Million USD | -89.804% |
| Forte Biosciences, Inc. | 32.47 Million USD | -1034.994% |
| Anebulo Pharmaceuticals, Inc. | 8.3 Million USD | -4336.429% |
| Enlivex Therapeutics Ltd. | 29.39 Million USD | -1153.996% |
| Conduit Pharmaceuticals Inc. | 5.56 Million USD | -6527.328% |
| SeaStar Medical Holding Corporation | 14.21 Million USD | -2494.032% |
| FibroBiologics, Inc. Common Stock | 8.88 Million USD | -4046.833% |
| Altimmune, Inc. | 30.55 Million USD | -1106.349% |
| LENZ Therapeutics, Inc. | 70.7 Million USD | -421.353% |
| Alpha Tau Medical Ltd. | -35.68 Million USD | 1133.105% |
| Peak Bio, Inc. | 1249.13 USD | -29509398.611% |
| Zevra Therapeutics, Inc. | 74.12 Million USD | -397.318% |
| Benitec Biopharma Inc. | 22.38 Million USD | -1546.913% |
| Spyre Therapeutics, Inc. | 243.18 Million USD | -51.574% |
| NKGen Biotech, Inc. Common Stock | 28.54 Million USD | -1191.427% |
| Zura Bio Limited | 62.63 Million USD | -488.48% |
| PolyPid Ltd. | 21.04 Million USD | -1651.542% |
| NKGen Biotech, Inc. Warrants | 28.54 Million USD | -1191.427% |
| argenx SE | 1.53 Billion USD | 75.963% |
| Immunome, Inc. | 122.82 Million USD | -200.124% |
| Verona Pharma plc | 67.15 Million USD | -448.928% |
| enGene Holdings Inc. Warrants | 25.88 Million USD | -1324.037% |
| Shattuck Labs, Inc. | 93.61 Million USD | -293.757% |
| CervoMed Inc. | 14.95 Million USD | -2364.352% |
| Plus Therapeutics, Inc. | 8.54 Million USD | -4214.279% |
| Dianthus Therapeutics, Inc. | 51 Million USD | -622.769% |
| Moolec Science SA | 52.75 Million USD | -598.782% |
| Enveric Biosciences, Inc. | 16.44 Million USD | -2141.015% |
| Design Therapeutics, Inc. | 78.19 Million USD | -371.431% |
| Leap Therapeutics, Inc. | 87.04 Million USD | -323.492% |
| Seelos Therapeutics, Inc. | 12.58 Million USD | -2828.979% |
| Achilles Therapeutics plc | 75.25 Million USD | -389.817% |
| CERo Therapeutics Holdings, Inc. | 2.93 Million USD | -12467.811% |
| CG Oncology, Inc. Common stock | 55.65 Million USD | -562.34% |
| Fractyl Health, Inc. Common Stock | 50.87 Million USD | -624.488% |
| Rani Therapeutics Holdings, Inc. | 66.09 Million USD | -457.667% |
| MoonLake Immunotherapeutics | 54.12 Million USD | -581.062% |
| Tourmaline Bio, Inc. | 45.4 Million USD | -711.76% |
| Beam Therapeutics Inc. | 554.19 Million USD | 33.487% |
| Mirum Pharmaceuticals, Inc. | 248.48 Million USD | -48.341% |
| AEON Biopharma, Inc. | 48.42 Million USD | -661.139% |
| Aadi Bioscience, Inc. | 93.47 Million USD | -294.33% |
| Enliven Therapeutics, Inc. | 83.52 Million USD | -341.298% |
| Kiora Pharmaceuticals, Inc. | 12.58 Million USD | -2828.538% |
| NeurAxis, Inc. | 8.82 Million USD | -4078.706% |
| Iovance Biotherapeutics, Inc. | 450.99 Million USD | 18.267% |
| Lumos Pharma, Inc. | 38.66 Million USD | -853.348% |
| Opiant Pharmaceuticals, Inc. | 26.5 Million USD | -1290.861% |
| Palisade Bio, Inc. | 13.32 Million USD | -2667.357% |
| Nutriband Inc. | 5.73 Million USD | -6328.497% |
| Taysha Gene Therapies, Inc. | 87.89 Million USD | -319.402% |
| Neurogene Inc. | 55.58 Million USD | -563.174% |
| Kintara Therapeutics, Inc. | 8.45 Million USD | -4261.756% |
| CARGO Therapeutics, Inc. Common Stock | 96.71 Million USD | -281.152% |
| Athira Pharma, Inc. | 125.46 Million USD | -193.794% |
| HCW Biologics Inc. | 21.02 Million USD | -1652.998% |
| XOMA Corporation | 46.46 Million USD | -693.345% |
| Nektar Therapeutics | 190.9 Million USD | -93.089% |
| Arvinas, Inc. | 480 Million USD | 23.206% |
| Tevogen Bio Holdings Inc. | 2.27 Million USD | -16110.064% |
| Merus N.V. | 200.49 Million USD | -83.852% |
| Omega Therapeutics, Inc. | 103.35 Million USD | -256.647% |
| Quince Therapeutics, Inc. | 34.62 Million USD | -964.737% |
| Rezolute, Inc. | 70.38 Million USD | -423.693% |
| Clene Inc. | 41.07 Million USD | -797.456% |
| Indaptus Therapeutics, Inc. | 16.37 Million USD | -2150.588% |
| BeyondSpring Inc. | 24.86 Million USD | -1382.453% |
| Synlogic, Inc. | 58.53 Million USD | -529.761% |
| Allarity Therapeutics, Inc. | 17.89 Million USD | -1960.206% |
| Phio Pharmaceuticals Corp. | 4.49 Million USD | -8105.966% |
| Peak Bio, Inc. | 1249.13 USD | -29509398.611% |
| Werewolf Therapeutics, Inc. | 60.44 Million USD | -509.82% |
| Krystal Biotech, Inc. | 160.42 Million USD | -129.771% |
| Karyopharm Therapeutics Inc. | 270.63 Million USD | -36.205% |
| SpringWorks Therapeutics, Inc. | 348.03 Million USD | -5.911% |
| Lipella Pharmaceuticals Inc. | 2.15 Million USD | -16991.213% |
| MannKind Corporation | 125.59 Million USD | -193.488% |
| Ikena Oncology, Inc. | 84.57 Million USD | -335.83% |
| Cyclerion Therapeutics, Inc. | 9.64 Million USD | -3721.001% |
| Gyre Therapeutics, Inc. | 89.6 Million USD | -311.393% |
| Gossamer Bio, Inc. | 183.75 Million USD | -100.595% |
| CohBar, Inc. | 12.38 Million USD | -2875.486% |
| Cognition Therapeutics, Inc. | 50.72 Million USD | -626.701% |
| NRx Pharmaceuticals, Inc. | 27.58 Million USD | -1236.422% |
| Legend Biotech Corporation | 583.14 Million USD | 36.789% |
| Mural Oncology plc | 192.07 Million USD | -91.914% |
| Disc Medicine, Inc. | 91.12 Million USD | -304.512% |
| Champions Oncology, Inc. | 28.11 Million USD | -1211.32% |
| REGENXBIO Inc. | 321.15 Million USD | -14.776% |
| Ensysce Biosciences, Inc. | 5.36 Million USD | -6775.507% |
| Anavex Life Sciences Corp. | 55.75 Million USD | -561.116% |
| Cellectar Biosciences, Inc. | 38.96 Million USD | -846.114% |
| Edgewise Therapeutics, Inc. | 114.35 Million USD | -222.334% |
| Vaxart, Inc. | 90.72 Million USD | -306.291% |
| PharmaCyte Biotech, Inc. | 8.52 Million USD | -4226.428% |
| Aldeyra Therapeutics, Inc. | 42.79 Million USD | -761.362% |
| Cellectis S.A. | 97.32 Million USD | -278.763% |
| Longeveron Inc. | 21.25 Million USD | -1634.645% |
| Repare Therapeutics Inc. | 167.35 Million USD | -120.255% |
| Sarepta Therapeutics, Inc. | 1.36 Billion USD | 72.912% |
| Inozyme Pharma, Inc. | 75.64 Million USD | -387.292% |
| Revolution Medicines, Inc. | 498.76 Million USD | 26.095% |
| Nymox Pharmaceutical Corporation | 6.65 Million USD | -5441.371% |
| Third Harmonic Bio, Inc. | 43.95 Million USD | -738.631% |
| ArriVent BioPharma, Inc. Common Stock | 74.59 Million USD | -394.184% |
| AN2 Therapeutics, Inc. | 69.63 Million USD | -429.349% |
| Anixa Biosciences, Inc. | 11.06 Million USD | -3232.839% |
| Vertex Pharmaceuticals Incorporated | 4.77 Billion USD | 92.28% |
| Denali Therapeutics Inc. | 527.23 Million USD | 30.085% |
| Revelation Biosciences, Inc. | 8.65 Million USD | -4158.13% |
| Veru Inc. | 101.34 Million USD | -263.709% |
| Corvus Pharmaceuticals, Inc. | 23.4 Million USD | -1474.794% |
| Cingulate Inc. | 22.75 Million USD | -1519.618% |
| Passage Bio, Inc. | 108.38 Million USD | -240.082% |
| Context Therapeutics Inc. | 25.07 Million USD | -1370.178% |
| Exicure, Inc. | 14.07 Million USD | -2518.727% |
| Day One Biopharmaceuticals, Inc. | 206.06 Million USD | -78.882% |
| Oramed Pharmaceuticals Inc. | 43.3 Million USD | -751.278% |
| Scinai Immunotherapeutics Ltd. | 9.17 Million USD | -3916.567% |
| Nuvalent, Inc. | 149.49 Million USD | -146.576% |
| ABVC BioPharma, Inc. | 8.06 Million USD | -4469.437% |
| Carisma Therapeutics, Inc. | 103.65 Million USD | -255.631% |
| Unicycive Therapeutics, Inc. | 21.44 Million USD | -1618.551% |
| OmniAb, Inc. | 83.89 Million USD | -339.373% |
| Anew Medical, Inc. | 1.3 Million USD | -28236.438% |
| Fennec Pharmaceuticals Inc. | 32.76 Million USD | -1025.052% |
| Lipocine Inc. | 15.08 Million USD | -2344.354% |
| Lexeo Therapeutics, Inc. Common Stock | 68.51 Million USD | -438.018% |
| Nautilus Biotechnology, Inc. | 76.15 Million USD | -384.048% |
| SAB Biotherapeutics, Inc. | 40.31 Million USD | -814.345% |
| G1 Therapeutics, Inc. | 114.84 Million USD | -220.97% |
| Bellerophon Therapeutics, Inc. | 22.38 Million USD | -1546.766% |
| Sage Therapeutics, Inc. | 664.14 Million USD | 44.498% |
| Ocugen, Inc. | 71.56 Million USD | -415.059% |
| Mind Medicine (MindMed) Inc. | 93.86 Million USD | -292.7% |
| Q32 Bio Inc. | 92.68 Million USD | -297.726% |
| Brainstorm Cell Therapeutics Inc. | 21.17 Million USD | -1640.871% |
| Alumis Inc. Common Stock | 158.17 Million USD | -133.042% |
| Equillium, Inc. | 50.6 Million USD | -628.396% |
| Kyverna Therapeutics, Inc. | 62.4 Million USD | -490.668% |
| Coya Therapeutics, Inc. | 13.9 Million USD | -2550.826% |
| CNS Pharmaceuticals, Inc. | 18.86 Million USD | -1853.935% |
| Dominari Holdings Inc. | 23.83 Million USD | -1446.516% |
| Edesa Biotech, Inc. | 9.22 Million USD | -3896.765% |
| vTv Therapeutics Inc. | 11.9 Million USD | -2995.759% |
| Bio-Techne Corporation | 563.03 Million USD | 34.532% |
| Agios Pharmaceuticals, Inc. | 408.8 Million USD | 9.832% |
| Harmony Biosciences Holdings, Inc. | 268.75 Million USD | -37.155% |
| Prelude Therapeutics Incorporated | 132.27 Million USD | -178.667% |
| Candel Therapeutics, Inc. | 14.41 Million USD | -2457.852% |
| iTeos Therapeutics, Inc. | 163.69 Million USD | -125.181% |
| Nkarta, Inc. | 131.65 Million USD | -179.994% |
| BioCardia, Inc. | 12.12 Million USD | -2941.102% |
| Iterum Therapeutics plc | 47.46 Million USD | -676.548% |